NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
about
The potential for caspases in drug discoveryClinical pharmacology of portal hypertension.Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.Nitric oxide in liver diseases.Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation.Current concepts on the role of nitric oxide in portal hypertension.Pathophysiology of portal hypertension and its clinical links.Novel treatment options for portal hypertension.Sinusoidal communication in liver fibrosis and regeneration.A novel liver-targeted nitric oxide donor UDCA-Thr-NO protects against cirrhosis and portal hypertension.Managing portal hypertension in patients with liver cirrhosis.Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension
P2860
Q33682384-B12E4DD3-F2A9-4B00-A7B0-98256AA4D71EQ34399357-A5EEF36F-1ABB-4D4E-AA0E-9B884A96FD62Q35651447-7E4B0E6E-9C7C-4139-8727-D1765CED1F41Q35940869-94CE2E5E-0DA2-458A-A598-418CA347BF40Q37959188-DD80A38C-D3B1-4803-B69C-A9985BF6F1D5Q38095931-3EB12008-55C2-434C-AA52-CE9D2B2C124AQ38371453-1D21D421-260C-49DB-B98C-D8F967B2366EQ38680437-D422B91B-673C-420E-A4A7-CE5D86BE01B2Q38827092-3211ADC8-D456-433F-B4B4-309CB1B41F2BQ52670963-1D74CC60-797A-4C79-B39F-E14581EA394CQ55278061-E16A85F8-753E-4A3A-9F54-C8CCCD1F615CQ57815107-7A9FCDAD-DA02-410B-AEE7-ED4831850A16
P2860
NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
NCX-1000, a nitric oxide-relea ...... -blind, dose-escalating study.
@en
NCX-1000, a nitric oxide-relea ...... -blind, dose-escalating study.
@nl
type
label
NCX-1000, a nitric oxide-relea ...... -blind, dose-escalating study.
@en
NCX-1000, a nitric oxide-relea ...... -blind, dose-escalating study.
@nl
prefLabel
NCX-1000, a nitric oxide-relea ...... -blind, dose-escalating study.
@en
NCX-1000, a nitric oxide-relea ...... -blind, dose-escalating study.
@nl
P2093
P2860
P356
P1476
NCX-1000, a nitric oxide-relea ...... e-blind, dose-escalating study
@en
P2093
Andrea De Gottardi
Annalisa Berzigotti
Caroline Gagnon
Jaime Bosch
Jean Spénard
Juan Carlos Garcia-Pagan
P2860
P304
P356
10.1038/AJG.2009.661
P407
P50
P577
2009-11-17T00:00:00Z